GlassScriptPhysician profile
Syed Husain
NPI 1174838825
$97,506.53
in general payments reported to CMS, 2019-2025
23 companies · $45K in 2025
The $45K reported for 2025 was more than what 96% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $66.72 · 2021: $477 · 2022: $350 · 2023: $17K · 2024: $35K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Consulting Fee: $12K · Honoraria: $11K · Travel and Lodging: $3,615 · Food and Beverage: $2,654 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,750.00 |
| Consulting Fee | $11,725.00 |
| Honoraria | $11,437.50 |
| Travel and Lodging | $3,615.39 |
| Food and Beverage | $2,653.56 |
| Education | $278.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $68,595.44 | 2019-2025 | Krystexxa, Tavneos, Otezla |
| Horizon Therapeutics Plc | $12,418.78 | 2021-2023 | Krystexxa |
| Abbvie INC. | $5,895.85 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $5,102.90 | 2024-2025 | |
| Ucb, INC. | $2,290.37 | 2020-2023 | Cimzia |
| Janssen Biotech, INC. | $1,758.70 | 2023-2024 | Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $316.67 | 2024-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $265.64 | 2023-2025 | Saphnelo |
| Livanova USA, INC. | $154.85 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $154.69 | 2023 | Arcalyst |
| Pfizer INC. | $128.82 | 2021-2025 | |
| Glaxosmithkline, LLC. | $77.08 | 2023-2024 | Benlysta |
| Aurinia Pharma U.S., INC. | $51.11 | 2025 | Lupkynis |
| Fresenius Kabi USA, LLC | $48.28 | 2024 | Idacio |
| Progenacare Global, LLC | $47.40 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $35.35 | 2024 | Arcalyst |
| Genentech USA, INC. | $28.91 | 2025 | Gazyva |
| Hikma Pharmaceuticals USA | $25.65 | 2020-2021 | |
| Genzyme Corporation | $23.47 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $23.19 | 2024 | Uptravi, Opsumit |
| Mylan Institutional INC. | $22.84 | 2023 | Hulio |
| Qiagen, LLC | $20.54 | 2021 | |
| Ani Pharmaceuticals, INC. | $20.00 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Husain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.